{"id":7964,"date":"2024-03-12T22:24:55","date_gmt":"2024-03-12T14:24:55","guid":{"rendered":"https:\/\/flcube.com\/?p=7964"},"modified":"2024-10-19T22:28:43","modified_gmt":"2024-10-19T14:28:43","slug":"innovent-and-hutchmeds-combination-therapy-set-for-priority-review-in-china-for-advanced-endometrial-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=7964","title":{"rendered":"Innovent and HutchMed&#8217;s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer"},"content":{"rendered":"\n<p>China&#8217;s Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics Inc.\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) PD-1 inhibitor Tyvyt (sintilimab injection) and HutchMed\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/0013:HKG\">HKG: 0013<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/HCM:NASDAQ\">NASDAQ: HCM<\/a>) Elunate (fruquintinib) is on track to receive priority review status in China. This designation pertains to the treatment of advanced mismatch repair proficient (pMMR) or non-MSI-H endometrial cancer in patients with disease progression following prior systemic anti-tumor therapy, particularly those unsuitable for curative surgery or radiotherapy. Notably, this combination previously received breakthrough therapy designation (BTD) in China.<\/p>\n\n\n\n<p>Since its launch in December 2018, Tyvyt has been approved for seven indications in mainland China, all included in the National Reimbursement Drug List (NRDL). These indications encompass: 1) recurrent or refractory classical Hodgkin lymphoma (cHL) after at least second-line systemic chemotherapy; 2) first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with negative mutations in the epidermal growth factor receptor (EGFR) gene and negative anaplastic lymphoma kinase (ALK); 3) locally advanced or metastatic NSCLC in EGFR-positive patients who have failed EGFR-targeted tyrosine kinase inhibitors (TKIs); 4) first-line treatment of unresectable locally advanced or metastatic squamous NSCLC; 5) first-line treatment of unresectable metastatic hepatocellular carcinoma (HCC) with no prior systemic treatment; 6) first-line treatment of unresectable locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC); and 7) first-line treatment of unresectable locally advanced recurrent or metastatic gastric adenocarcinoma and gastroesophageal junction (GC\/GEJ) cancers.<\/p>\n\n\n\n<p>Elunate, a highly selective oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, was approved by the NMPA in September 2018 and launched commercially in November of the same year for metastatic colorectal cancer (mCRC) patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan, including those who had received anti-VEGF and\/or anti-EGFR therapies (RAS wild type). In March 2023, HutchMed entered into a USD 1.13 billion licensing agreement with Takeda, granting the latter global development, commercialization, and manufacturing rights for Elunate, excluding mainland China, Hong Kong, and Macau.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,29,1105,910,285,198,1104,18,80],"class_list":["post-7964","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-combination-therapy","tag-hkg-0013","tag-hkg-1801","tag-hutchmed","tag-innovent-biologics","tag-nasdaq-hcm","tag-pd-1-l1","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent and HutchMed&#039;s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics Inc.\u2019s (HKG: 1801) PD-1 inhibitor Tyvyt (sintilimab injection) and HutchMed\u2019s (HKG: 0013, NASDAQ: HCM) Elunate (fruquintinib) is on track to receive priority review status in China. This designation pertains to the treatment of advanced mismatch repair proficient (pMMR) or non-MSI-H endometrial cancer in patients with disease progression following prior systemic anti-tumor therapy, particularly those unsuitable for curative surgery or radiotherapy. Notably, this combination previously received breakthrough therapy designation (BTD) in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=7964\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent and HutchMed&#039;s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=7964\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-12T14:24:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-19T14:28:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7964#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7964\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent and HutchMed&#8217;s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer\",\"datePublished\":\"2024-03-12T14:24:55+00:00\",\"dateModified\":\"2024-10-19T14:28:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7964\"},\"wordCount\":332,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Combination therapy\",\"HKG: 0013\",\"HKG: 1801\",\"HutchMed\",\"Innovent Biologics\",\"NASDAQ: HCM\",\"PD-1\\\/L1\",\"Priority reviews\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7964#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7964\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=7964\",\"name\":\"Innovent and HutchMed's Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-03-12T14:24:55+00:00\",\"dateModified\":\"2024-10-19T14:28:43+00:00\",\"description\":\"China's Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics Inc.\u2019s (HKG: 1801) PD-1 inhibitor Tyvyt (sintilimab injection) and HutchMed\u2019s (HKG: 0013, NASDAQ: HCM) Elunate (fruquintinib) is on track to receive priority review status in China. This designation pertains to the treatment of advanced mismatch repair proficient (pMMR) or non-MSI-H endometrial cancer in patients with disease progression following prior systemic anti-tumor therapy, particularly those unsuitable for curative surgery or radiotherapy. Notably, this combination previously received breakthrough therapy designation (BTD) in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7964#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7964\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7964#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent and HutchMed&#8217;s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent and HutchMed's Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"China's Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics Inc.\u2019s (HKG: 1801) PD-1 inhibitor Tyvyt (sintilimab injection) and HutchMed\u2019s (HKG: 0013, NASDAQ: HCM) Elunate (fruquintinib) is on track to receive priority review status in China. This designation pertains to the treatment of advanced mismatch repair proficient (pMMR) or non-MSI-H endometrial cancer in patients with disease progression following prior systemic anti-tumor therapy, particularly those unsuitable for curative surgery or radiotherapy. Notably, this combination previously received breakthrough therapy designation (BTD) in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=7964","og_locale":"en_US","og_type":"article","og_title":"Innovent and HutchMed's Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=7964","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-03-12T14:24:55+00:00","article_modified_time":"2024-10-19T14:28:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=7964#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=7964"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent and HutchMed&#8217;s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer","datePublished":"2024-03-12T14:24:55+00:00","dateModified":"2024-10-19T14:28:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=7964"},"wordCount":332,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Combination therapy","HKG: 0013","HKG: 1801","HutchMed","Innovent Biologics","NASDAQ: HCM","PD-1\/L1","Priority reviews"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=7964#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=7964","url":"https:\/\/flcube.com\/?p=7964","name":"Innovent and HutchMed's Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-03-12T14:24:55+00:00","dateModified":"2024-10-19T14:28:43+00:00","description":"China's Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics Inc.\u2019s (HKG: 1801) PD-1 inhibitor Tyvyt (sintilimab injection) and HutchMed\u2019s (HKG: 0013, NASDAQ: HCM) Elunate (fruquintinib) is on track to receive priority review status in China. This designation pertains to the treatment of advanced mismatch repair proficient (pMMR) or non-MSI-H endometrial cancer in patients with disease progression following prior systemic anti-tumor therapy, particularly those unsuitable for curative surgery or radiotherapy. Notably, this combination previously received breakthrough therapy designation (BTD) in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=7964#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=7964"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=7964#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent and HutchMed&#8217;s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7964"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7964\/revisions"}],"predecessor-version":[{"id":7965,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7964\/revisions\/7965"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}